Business UpdateAug 12, 2026, 08:45 AM
AIM ImmunoTech CEO Article Highlights Ampligen's Antiviral Potential
AI Summary
AIM ImmunoTech announced its CEO, Thomas K. Equels, published an article in "Breaking Defense" advocating for proactive evaluation of broad-spectrum antiviral countermeasures. The article highlights the company's investigational drug, Ampligen (rintatolimod), and its potential as a prophylactic or early-onset antiviral against Ebola and its variants, citing preclinical research. Equels emphasizes integrating biodefense into military force protection planning, urging evaluation of promising countermeasures before new viral threats emerge.
Key Highlights
- CEO Thomas K. Equels published an article advocating proactive biodefense strategies.
- Article highlights Ampligen's potential as a broad-spectrum prophylactic/early-onset antiviral.
- Preclinical Ebola research showed 100% survival in Ampligen-treated mice vs. 100% mortality in controls.
- Advocates for evaluating promising countermeasures through government-supported and FDA-regulated pathways.
- Mentions past preclinical research on Ampligen for SARS-related coronaviruses.
- Equels emphasizes integrating prophylactic antiviral countermeasures into defense planning.
Price Impact
More from AIM